Equities research analysts expect BioScrip Inc (NASDAQ:BIOS) to post sales of $171.79 million for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for BioScrip’s earnings, with the lowest sales estimate coming in at $170.49 million and the highest estimate coming in at $173.40 million. BioScrip posted sales of $240.12 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 28.5%. The business is scheduled to issue its next earnings report on Friday, March 2nd.
According to Zacks, analysts expect that BioScrip will report full-year sales of $171.79 million for the current financial year, with estimates ranging from $805.10 million to $808.00 million. For the next fiscal year, analysts forecast that the business will post sales of $722.13 million per share, with estimates ranging from $695.23 million to $734.93 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for BioScrip.
Several research analysts have recently issued reports on BIOS shares. ValuEngine upgraded shares of BioScrip from a “strong sell” rating to a “sell” rating in a report on Thursday, November 9th. BidaskClub upgraded shares of BioScrip from a “hold” rating to a “buy” rating in a report on Thursday, January 4th. SunTrust Banks set a $4.00 price objective on shares of BioScrip and gave the stock a “buy” rating in a report on Thursday, December 21st. Finally, Zacks Investment Research upgraded shares of BioScrip from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $3.63.
BioScrip (BIOS) remained flat at $$2.93 during trading on Monday. The company’s stock had a trading volume of 392,683 shares, compared to its average volume of 936,859. The stock has a market cap of $373.62, a price-to-earnings ratio of -4.73 and a beta of 0.19. The company has a debt-to-equity ratio of -6.11, a quick ratio of 1.60 and a current ratio of 1.91. BioScrip has a 12-month low of $1.35 and a 12-month high of $3.39.
Several large investors have recently bought and sold shares of the company. Gilder Gagnon Howe & Co. LLC increased its stake in BioScrip by 3.6% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 15,764,337 shares of the company’s stock valued at $43,352,000 after acquiring an additional 553,201 shares during the period. Gabelli Funds LLC increased its stake in BioScrip by 2.0% in the fourth quarter. Gabelli Funds LLC now owns 10,357,832 shares of the company’s stock valued at $30,141,000 after acquiring an additional 205,379 shares during the period. BlackRock Inc. increased its stake in BioScrip by 10.2% in the fourth quarter. BlackRock Inc. now owns 6,584,105 shares of the company’s stock valued at $19,161,000 after acquiring an additional 611,302 shares during the period. FMR LLC increased its stake in BioScrip by 10.8% in the second quarter. FMR LLC now owns 5,323,231 shares of the company’s stock valued at $14,453,000 after acquiring an additional 520,231 shares during the period. Finally, Vanguard Group Inc. increased its stake in BioScrip by 3.4% in the second quarter. Vanguard Group Inc. now owns 4,495,029 shares of the company’s stock valued at $12,204,000 after acquiring an additional 146,980 shares during the period. Institutional investors own 85.51% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://ledgergazette.com/2018/02/19/bioscrip-inc-bios-expected-to-post-quarterly-sales-of-171-79-million.html.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.